Cornelia Tillack-Schreiber
Lipocalin-2 Is a Disease Activity Marker in Inflammatory Bowel Disease Regulated by IL-17A, IL-22, and TNF-α and Modulated by IL23R Genotype Status
Stallhofer J, Beigel F, Schnitzler F, Tillack-Schreiber C, Glas J, Lohse P, Wetzke M, Konrad-Zerna A, Friedrich M, Brand S. Lipocalin-2 Is a Disease Activity Marker in Inflammatory Bowel Disease Regulated by IL-17A, IL-22, and TNF-α and Modulated by IL23R Genotype Status. Inflamm Bowel Dis 2015; 21:2327-40.
01.10.2015Lipocalin-2 Is a Disease Activity Marker in Inflammatory Bowel Disease Regulated by IL-17A, IL-22, and TNF-α and Modulated by IL23R Genotype Status
01.10.2015Inflamm Bowel Dis 2015; 21:2327-40
Stallhofer Johannes, Beigel Florian, Schnitzler Fabian, Tillack-Schreiber Cornelia, Glas Jürgen, Lohse Peter, Wetzke Martin, Konrad-Zerna Astrid, Friedrich Matthias, Brand Stephan
Malignant melanoma during ustekinumab therapy of Crohn's disease
Ehmann L, Tillack-Schreiber C, Brand S, Wollenberg A. Malignant melanoma during ustekinumab therapy of Crohn's disease. Inflamm Bowel Dis 2011; 18:E199-200.
10.10.2011Malignant melanoma during ustekinumab therapy of Crohn's disease
10.10.2011Inflamm Bowel Dis 2011; 18:E199-200
Ehmann Laura M, Tillack-Schreiber Cornelia, Brand Stephan, Wollenberg Andreas